"Designing Growth Strategies is in our DNA"

Molecular Diagnostics Market Size, Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025

Region : Global | Latest Update: Jul, 2019 | Published Date: Apr, 2019 | Report ID: FBI100086| Status : Published



The Global Molecular Diagnostics Market accounted for a Revenue of US$ 8,012.7 Mn in 2017, and is Expected to Reach US$ 13,873.6 Mn by the End of 2025, with a CAGR of 7.1%. During the last decade, molecular diagnostics has emerged as a superior methodology and achieved the goal of faster disease diagnosis along with minimal complexities.

The demand for molecular diagnostics is higher, particularly for the diagnosis of infectious diseases. The growing prevalence of infectious diseases in both developing and developed nations is boosting the demand for molecular diagnosis. Major viral and bacterial outbreaks in the Middle East & Africa forced all governments and research institutions across the globe to adopt molecular diagnostics to inhibit the microbial outbreaks.

Get comprehensive study about this report by, request a sample copy

In terms of techniques, the amplification techniques segment is projected to hold considerable share in the global molecular diagnostics market. Consumables and reagent segments are also expected to hold considerable share in the global molecular diagnostics market. 

Infectious Diseases considered to be the Most Attractive Application

Currently, managing the microbial outbreaks and infections across the globe is a big challenge faced by all the governments worldwide. Huge amount of resource engagement in terms of technology, expertise and finance serves, and favorable environment for the imitation of research projects, particularly for infectious diseases is boosting the market for molecular diagnostics. The Infectious diseases application segment accounted for a market share of 60.0 % in 2017. Moreover, rise in awareness programs initiated by global organizations such as World Health Organization (WHO), World Bank and others for infectious diseases are expected to encourage the talent pool to step forward with the aim to achieve higher utilization of molecular diagnostics.

To get details on market share, speak to our analyst

In terms of product type, reagents and consumables considered to hold majority share owing to higher demand over instruments. In terms of techniques, amplification techniques are anticipated to hold majority share owing to efficiency of these techniques for faster and accurate disease diagnosis. Moreover, sequencing techniques represents higher growth during the forecast period. Various end users in the global molecular diagnostics market are clinical & pathology labs, hospitals, and others (physicians’ offices, clinics, emergency centers, long-term & urgent care centers, etc). Lucrative reimbursement strategies offered by the government for the implementation of molecular diagnostics signifies considerable growth in the execution of molecular diagnostics in clinical & pathology labs as well as in hospitals.

Reinforcement Strategies of Government Institutions for Molecular Diagnostics Reflected as Higher Growth of the Market in North America

North America generated a revenue of US$ 3,639.4 Mn in 2017, and is anticipated to emerge dominant in the global molecular diagnostics market during the forecast period. Growth witnessed in the region is likely to be driven by the increasing association and collaborative efforts taken by both large academic institutions and research hospitals. Moreover, the increasing interactions between hospital research organizations and academic institutions for process improvements will help boost the market. The utilization of large amount of molecular diagnostics for improvisation of clinical efficiency are projected to offer significant growth for the molecular diagnostic market during the forecast period. Moreover, the rising emphasis of bigger hospital research and clinical microbiology organizations, and their collective efforts to increase the level of molecular diagnostics are expected to drive the molecular diagnostics market in Europe. Though, improvements in Asia Pacific are currently in premature stage, rapidly developing infrastructure and increasing investments in research and development are anticipated to serve huge potentials for the growth of the molecular diagnostics market in Asia Pacific.

North America Molecular Diagnostics Market, 2017

To get geographical overview of this market, request a sample copy

QIAGEN, F. Hoffmann-La Roche Ltd., Danaher, and Abbott Expected to Hold Considerable Share in the Global Molecular Diagnostics Market

Giant organizations such as QIAGEN, F. Hoffmann-La Roche Ltd., Danaher, Abbott are expected to lead the global molecular diagnostics market during the forecast period. Optimal research & development strategies, robust supply chain network, increasing investments in research & development and cost management are projected to serve huge opportunity for the aforementioned market players to lead the global molecular diagnostics market during the forecast period. Moreover, higher potential for intense penetration of molecular diagnostics in the Asia Pacific market may offer significant share for the companies in terms of revenue in the global molecular diagnostics market.


The science of medical diagnostics is witnessing remarkable achievements in terms of new diagnostic domains and philosophies. The popularity of molecular diagnostics is continuously increasing in life sciences due to its extensive applications, promising solutions, and methodologies for disease diagnosis on molecular level.

The report provides both qualitative and quantitative insights on molecular diagnostics industry and detailed analysis of market size & growth rate for all possible segments in the market. The market is segmented into product type, application, technique, and end user. On the basis of product type, the global molecular diagnostics market is categorized into instruments and reagents & consumables. Based on applications, the global molecular diagnostics market is segmented into infectious disease, blood screening, histology, oncology, and others. Based on techniques, the global molecular diagnostics market is segmented into amplification techniques, hybridization techniques, sequencing techniques, and others. Various end users covered in the report are clinical and pathology laboratories, hospitals, and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. These regions are further categorized into countries.

Along with this, the report provides an elaborative analysis of the market dynamics and a competitive landscape. Various key insights provided in the report are Porter’s five forces analysis, recent advancements in molecular diagnostics, key mergers & acquisitions, and others.



To get information on various segments, share your queries with us




By Product Type

·      Instruments

·      Reagents & Consumables

By Application

·      Infectious Disease

·      Blood Screening

·      Histology

·      Oncology

·      Others

By Technique

·      Hospitals Amplification Techniques

·      Hybridization Techniques

·      Sequencing Techniques

·      Others

By End User

·      Hospitals

·      Clinical & Pathology Labs

·      Others

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



  • BioMérieux SA.
  • BD
  • Danaher
  • Grifols, S.A.
  • Hologic Inc.
  • Novartis AG
  • Siemens Healthcare GmbH
  • Hoffmann-La Roche Ltd.
  • Other players

Molecular Diagnostic Industry Developments

  • In May 2019, Qiagen, a Germany based company got FDA approval for its QIAstat-Dx syndromic testing system. The newly FDA approved system is equipped with an advanced DiagCORE technology which enables effective detection of around 20 types of pathogens.

  • In April 2018, altona Diagnostics GmbH launched an advanced marked AltoStar Molecular Diagnostic Workflow with an aim to streamline the workflow in real-time PCR infectious disease testing.

  • In July 2015, Rosetta Genomics Ltd. launched OncoGxSelect, a next-generation sequencing oncology panel. The new system enables detection of 5 types of genes which are associated with lung cancer.

Molecular Diagnostics Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2017
  • 2014-2016
  • 155


  • 4850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.